■2019.3.26

TME Therapeutics Inc. (TME) and Sanwa Kagaku Kenkyusho Co., Ltd. (SKK) have reached an agreement for TME to license its oligonucleotide product candidate to SKK.

■2018.4.26

Results of IIT for unresectable pancreatic cancer was published in GIE.

Nishimura M, et al. Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival in patients with unresectable pancreatic cancer. Gastrointest Endosc. 87:1126-1131, 2018.

https://www.ncbi.nlm.nih.gov/pubmed/29122598